Eloxx Pharmaceuticals (Uplisting)(ELOX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ELOX Eloxx Pharmaceuticals (Uplisting)

盘前交易 10-15 04:01:50 EDT

12.21

-0.49

-3.86%

最高13.23	最低12.21	成交量1.26万
今开13.13	昨收12.70	日振幅8.00%
总市值4,928万	流通市值2,913万	总股本403.63万
成交额16.11万	换手率0.53%	流通股本238.56万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ELOX","market":"US","secType":"STK","nameCN":"Eloxx Pharmaceuticals (Uplisting)","latestPrice":12.21,"timestamp":1792008000000,"preClose":12.7,"halted":0,"volume":12550,"delay":0,"changeRate":-0.03858267716535421,"floatShares":2385600,"shares":4036314,"eps":-2.849267,"marketStatus":"盘前交易","change":-0.49,"latestTime":"10-15 04:01:50 EDT","open":13.13,"high":13.2257,"low":12.21,"amount":161070.84149999998,"amplitude":0.079976,"askPrice":19.53,"askSize":200,"bidPrice":4.89,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.849267,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792071000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1780459200000,"exchange":"NASDAQ","adjPreClose":12.21,"postHourTrading":{"tag":"盘后","latestPrice":12.21,"preClose":12.21,"latestTime":"19:30 EDT","volume":7,"amount":85.47,"timestamp":1792020600424,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5971868004004218,"impliedVol":6.0667,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ELOX","defaultTab":"news","newsList":[{"id":"1191128181","title":"Eloxx Pharmaceuticals获Leerink Partners首次覆盖，给予跑赢大盘评级，目标价32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191128181","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191128181?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:07","pubTimestamp":1789726021,"startTime":"0","endTime":"0","summary":"Leerink Partners正式启动对Eloxx Pharmaceuticals的覆盖研究，并给予其“跑赢大盘”评级。这家投资机构同时设定了每股32美元的目标价格，为市场参与者提供了明确的参考基准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109390421","title":"Eloxx制药宣布EXACT二期B研究完成首批患者给药，针对无义突变Alport综合征的Exaluren疗法迎来关键进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1109390421","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109390421?lang=zh_cn&edition=full","pubTime":"2026-09-11 19:31","pubTimestamp":1789126293,"startTime":"0","endTime":"0","summary":"Eloxx制药近日正式宣布，其用于治疗无义突变Alport综合征的在研药物Exaluren，已在EXACT二期B临床试验中完成首批患者给药。这一里程碑式的进展，标志着该潜在疗法在临床开发道路上迈出了坚实且重要的一步。Exaluren作为一种新型的读出机制药物，旨在通过诱导核糖体通读提前出现的终止密码子，从而恢复全长功能性蛋白质的生成。此次研究的启动，不仅为饱受这种罕见遗传性肾病困扰的患者群体带来了新的希望，也进一步验证了公司在该领域的专业布局与科研实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194928881","title":"Eloxx Pharmaceuticals：16周研究顶线数据预计2027年中公布，最终读数2027年底揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1194928881","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194928881?lang=zh_cn&edition=full","pubTime":"2026-09-11 19:31","pubTimestamp":1789126274,"startTime":"0","endTime":"0","summary":"Eloxx Pharmaceuticals披露了其关键研发管线的最新时间表。这家生物制药公司预计，备受瞩目的16周研究顶线数据将于2027年年中对外发布。紧随其后，完整研究的最终读数则锁定在2027年年底前尘埃落定。Eloxx Pharmaceuticals的研发策略显然经过了精心设计。随着2027年渐行渐近，Eloxx Pharmaceuticals的一举一动料将吸引更多关注目光。届时，数据读出质量将直接决定市场对其在研疗法临床价值与商业潜力的最终定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELOX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2477933890","title":"美国OTC市场Eloxx Pharmaceuticals, Inc.盘中异动 大幅拉升20000.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477933890","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2477933890?lang=zh_cn&edition=full","pubTime":"2024-10-22 03:06","pubTimestamp":1729537561,"startTime":"0","endTime":"0","summary":"北京时间2024年10月22日03时06分，美国OTC市场Eloxx Pharmaceuticals, Inc.股票出现波动，股价大幅上涨20000.00%。截至发稿，该股报0.040美元/股，成交量214股，换手率0.01%，振幅0.00%。美国OTC市场Eloxx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.84%。其相关个股中，Genprex, Inc.、Biovie Inc.、Gri Bio, Inc.涨幅较大，Genprex, Inc.、Gri Bio, Inc.、Biovie Inc.较为活跃，换手率分别为9950.25%、3638.59%、1648.31%，振幅较大的相关个股有Genprex, Inc.、Biovie Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为369.73%、157.02%、151.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410220306019f547a0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410220306019f547a0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ELOX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eloxxpharma.com","stockEarnings":[{"period":"1week","weight":-0.1794},{"period":"1month","weight":-0.2509},{"period":"3month","weight":0.0158},{"period":"6month","weight":110},{"period":"1year","weight":122099},{"period":"ytd","weight":122099}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0115},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.0837},{"period":"1year","weight":0.1621},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Eloxx Pharmaceuticals, Inc.是一家全球性生物制药公司。该公司是一家临床阶段的生物制药公司，致力于开发新型小分子候选药物，旨在调节核糖体并促进由无义突变引起的提前终止密码子的通读，从而实现全长蛋白质的合成。靶向核糖体亚基为治疗多种遗传疾病提供了一种新的治疗策略。该公司目前的重点是推进其候选药物exaluren的临床开发，用于治疗罕见肾脏疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.000059},{"month":2,"riseRate":0.5,"avgChangeRate":93762.362207},{"month":3,"riseRate":0.375,"avgChangeRate":100.685333},{"month":4,"riseRate":0.625,"avgChangeRate":12.738428},{"month":5,"riseRate":0.333333,"avgChangeRate":0.064981},{"month":6,"riseRate":0.444444,"avgChangeRate":4.025146},{"month":7,"riseRate":0.444444,"avgChangeRate":0.018771},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.061007},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.133103},{"month":10,"riseRate":0.222222,"avgChangeRate":22.032858},{"month":11,"riseRate":0.25,"avgChangeRate":-0.236503},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.020438}],"exchange":"NASDAQ","name":"Eloxx Pharmaceuticals (Uplisting)","nameEN":"Eloxx Pharmaceuticals (Uplisting)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eloxx Pharmaceuticals (Uplisting)(ELOX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Eloxx Pharmaceuticals (Uplisting)(ELOX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Eloxx Pharmaceuticals (Uplisting),ELOX,Eloxx Pharmaceuticals (Uplisting)股票,Eloxx Pharmaceuticals (Uplisting)股票老虎,Eloxx Pharmaceuticals (Uplisting)股票老虎国际,Eloxx Pharmaceuticals (Uplisting)行情,Eloxx Pharmaceuticals (Uplisting)股票行情,Eloxx Pharmaceuticals (Uplisting)股价,Eloxx Pharmaceuticals (Uplisting)股市,Eloxx Pharmaceuticals (Uplisting)股票价格,Eloxx Pharmaceuticals (Uplisting)股票交易,Eloxx Pharmaceuticals (Uplisting)股票购买,Eloxx Pharmaceuticals (Uplisting)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eloxx Pharmaceuticals (Uplisting)(ELOX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Eloxx Pharmaceuticals (Uplisting)(ELOX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}